UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

Form 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2011

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 001-11789

ENCISION INC.

(Exact name of registrant as specified in its charter)

Colorado		84-1162056
(State or other jurisdiction of		(I.R.S. Employer Identification No.)
incorporation or organization)

6797 Winchester Circle

Boulder, Colorado 80301

(Address of principal executive offices)

(303) 444-2600

(Registrant’s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o		Accelerated filer o

Non-accelerated filer o		Smaller reporting company x
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

Indicate the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date:

(Class)		(outstanding at October 31, 2011)
Common Stock, no par value		6,455,100 Shares

Table of Contents

PART I FINANCIAL INFORMATION

ITEM 1 — CONDENSED INTERIM FINANCIAL STATEMENTS

Encision Inc.

Condensed Balance Sheets

(unaudited)

	September 30, 2011			March 31, 2011
ASSETS
Current assets:
Cash and cash equivalents	$	15,126		$	120,008
Accounts receivable, net of allowance for doubtful accounts of $4,000 at September 30, 2011 and $9,000 at March 31, 2011	1,101,313			1,160,008
Inventories, net of reserve for obsolescence of $115,000 at September 30, 2011 and $60,000 at March 31, 2011	2,688,457			2,603,873
Prepaid expenses	122,374			74,635
Total current assets	3,927,270			3,958,524
Equipment, at cost:
Furniture, fixtures and equipment	2,913,754			2,578,637
Customer-site equipment	814,357			814,357
Accumulated depreciation	(2,347,623		)	(2,224,371		)
Equipment, net	1,380,488			1,168,623
Patents, net of accumulated amortization of $163,822 at September 30, 2011 and $157,971 at March 31, 2011	269,002			260,097
Other assets	1,159			23,624
TOTAL ASSETS	$	5,577,919		$	5,410,868
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	727,525		$	673,538
Accrued compensation	233,545			261,269
Other accrued liabilities	617,253			287,067
Line of credit	691,012			435,000
Total current liabilities	2,269,335			1,656,874
Commitments and contingencies
Shareholders’ equity:
Preferred stock, no par value: 10,000,000 shares authorized; none issued and outstanding	—			—
Common stock and additional paid-in capital, no par value: 100,000,000 shares authorized; 6,455,100 shares issued and outstanding	19,827,702			19,783,361
Accumulated (deficit)	(16,519,118		)	(16,029,367		)
Total shareholders’ equity	3,308,584			3,753,994
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$	5,577,919		$	5,410,868

The accompanying notes to financial statements are an integral part of these condensed statements.

Table of Contents

Encision Inc.

Condensed Statements of Operations

(Unaudited)

Three Months Ended	September 30, 2011			September 30, 2010
NET REVENUE:
Product	$	2,830,369		$	2,865,799
Service	436,789			—
Total Revenue	3,267,158			2,865,799
COST OF REVENUE:
Product	1,525,244			1,031,576
Service	175,717			—
Total Cost of Revenue	1,700,961			1,031,576
GROSS PROFIT	1,566,197			1,834,223
OPERATING EXPENSES:
Sales and marketing	1,212,878			1,075,664
General and administrative	462,907			396,968
Research and development	342,173			494,578
Total operating expenses	2,017,958			1,967,210
OPERATING LOSS	(451,761		)	(132,987		)
Interest expense, net	(17,908		)	(12,824		)
Other income, net	294			443
Interest and other income, net	(17,614		)	(12,381		)
LOSS BEFORE PROVISION FOR INCOME TAXES	(469,375		)	(145,368		)
Provision for income taxes	—			—
NET LOSS	$	(469,375	)	$	(145,368	)
Net loss per share—basic and diluted	$	(0.07	)	$	(0.02	)
Weighted average shares—basic and diluted	6,455,100			6,455,100

The accompanying notes to financial statements are an integral part of these condensed statements.

Table of Contents

Encision Inc.

Condensed Statements of Operations

(Unaudited)

Six Months Ended	September 30, 2011			September 30, 2010
NET REVENUE:
Product	$	5,663,574		$	5,729,732
Service	787,578			48,688
Total Revenue	6,451,152			5,778,420
COST OF REVENUE:
Product	2,785,920			2,055,067
Service	319,909			44,802
Total Cost of Revenue	3,105,829			2,099,869
GROSS PROFIT	3,345,323			3,678,551
OPERATING EXPENSES:
Sales and marketing	2,250,318			2,261,471
General and administrative	881,696			792,876
Research and development	672,765			866,549
Total operating expenses	3,804,779			3,920,896
OPERATING LOSS	(459,456		)	(242,345		)
Interest expense, net	(30,920		)	(22,783		)
Other income, net	625			964
Interest and other income, net	(30,295		)	(21,819		)
LOSS BEFORE PROVISION FOR INCOME TAXES	(489,751		)	(264,164		)
Provision for income taxes	—			—
NET LOSS	$	(489,751	)	$	(264,164	)
Net loss per share—basic and diluted	$	(0.08	)	$	(0.04	)
Weighted average shares—basic and diluted	6,455,100			6,455,100

The accompanying notes to financial statements are an integral part of these condensed statements.

Table of Contents

Encision Inc.

Condensed Statements of Cash Flows

(Unaudited)

Six Months Ended	September 30, 2011			September 30, 2010
Cash flows from operating activities:
Net loss	$	(489,751	)	$	(264,164	)
Adjustments to reconcile loss to net cash provided by operating activities:
Depreciation and amortization	129,103			131,248
Stock-based compensation expense related to stock options	44,341			52,660
Provision for doubtful accounts, net	(5,000		)	3,500
Provision for inventory obsolescence, net	55,000			(80,940		)
Change in operating assets and liabilities:
Accounts receivable	63,695			324,412
Inventories	(139,584		)	26,303
Prepaid expenses and other assets	(25,274		)	(21,325		)
Accounts payable	53,987			(167,410		)
Accrued compensation and other accrued liabilities	302,462			(45,124		)
Net cash (used in) operating activities	(11,021		)	(40,840		)
Cash flows from investing activities:
Acquisition of property and equipment	(335,117		)	(145,310		)
Patent costs	(14,756		)	(3,821		)
Net cash (used in) investing activities	(349,873		)	(149,131		)
Cash flows from financing activities:
Borrowings from credit facility	256,012			231,263
Net cash provided by financing activities	256,012			231,263
Net increase (decrease) in cash and cash equivalents	(104,882		)	41,292
Cash and cash equivalents, beginning of period	120,008			113,735
Cash and cash equivalents, end of period	$	15,126		$	155,027

The accompanying notes to financial statements are an integral part of these condensed statements.

Table of Contents

ENCISION INC.

NOTES TO CONDENSED INTERIM FINANCIAL STATEMENTS

SEPTEMBER 30, 2011

(Unaudited)

Note 1. ORGANIZATION AND NATURE OF BUSINESS

Encision Inc. is a medical device company that designs, develops, manufactures and markets patented surgical instruments that provide greater safety to patients undergoing minimally-invasive surgery. We believe that our patented AEM® (Active Electrode Monitoring) surgical instrument technology is changing the marketplace for electrosurgical devices and instruments by providing a solution to a patient safety risk in laparoscopic surgery. Our sales to date have been made principally in the United States.

We have an accumulated deficit of $16,519,118 at September 30, 2011. Operating funds have been provided primarily by issuances of our common stock, the exercise of stock options to purchase our common stock and, in recent years, by operating profits. Should our liquidity be diminished in the future because of operating losses, we may be required to seek additional capital in the future. There are no assurances that additional capital will be available to us on terms acceptable to us, or at all.

Our strategic marketing and sales plan is designed to expand the use of our products in surgically active hospitals and surgery centers in the United States.

Note 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation. The condensed interim financial statements included herein have been prepared by us, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles accepted in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations, although we believe that the disclosures made are adequate to make the information presented not misleading. The condensed interim financial statements and notes thereto should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2011, filed on June 15, 2011.

The accompanying condensed interim financial statements have been prepared, in all material respects, in conformity with the standards of accounting measurements and reflect, in the opinion of management, all adjustments necessary to summarize fairly the financial position and results of operations for such periods in accordance with GAAP. All adjustments are of a normal recurring nature. The results of operations for the most recent interim period are not necessarily indicative of the results to be expected for the full year.

Use of Estimates in the Preparation of Financial Statements. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions. Such estimates and assumptions affect the reported amounts of assets and liabilities as well as disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of sales and expense during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents. For purposes of reporting cash flows, we consider all cash and highly liquid investments with an original maturity of three months or less to be cash equivalents.

Fair Value of Financial Instruments. Our financial instruments consist of cash and cash equivalents, short-term trade receivables and payables and a line of credit. The carrying values of cash and cash equivalents, short-term trade receivables and payables approximate their fair value due to their short maturities. The interest rate associated with the line of credit is variable and based upon fluctuations of the prime rate, thus the carrying value approximates fair value.

Concentration of Credit Risk. Financial instruments, which potentially subject us to concentrations of credit risk, consist of cash and cash equivalents, accounts receivable and a line of credit. The amount of cash on deposit with financial institutions does not exceed the $250,000 federally insured limit at September 30, 2011. However, we believe that in the event that cash on deposit exceeds $250,000, the financial institutions are financially sound and the risk of loss is minimal.

We have no significant off-balance sheet concentrations of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements. We maintain the majority of our cash balances with one financial institution in the form of demand deposits.

Accounts receivable are typically unsecured and are derived from transactions with and from entities in the healthcare industry primarily located in the United States. Accordingly, we may be exposed to credit risk generally associated with the healthcare industry. We maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. The net accounts receivable balance at September 30, 2011 of $1,101,313 included 11% from one customer. The net accounts receivable balance at March 31, 2011 of $1,160,008 included 13% from one customer.

Warranty Accrual. We provide for the estimated cost of product warranties at the time sales are recognized. While we engage in extensive product quality programs and processes, including actively monitoring and evaluating the quality of our component suppliers, our warranty obligation is based upon historical experience and is also affected by product failure rates and material usage incurred in correcting a product failure. Should actual product failure rates or material usage costs differ from our estimates, revisions to the estimated warranty liability would be required. The warranty accrual balance at September 30, 2011 of approximately $344,000 increased principally as a result of our voluntary recall of product, as explained herein, from the warranty accrual balance of $25,000 at March 31, 2011.

Table of Contents

Inventories. Inventories are stated at the lower of cost (first-in, first-out basis) or market. We reduce inventory for estimated obsolete or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. At September 30, 2011 and March 31, 2011, inventory consisted of the following:

	September 30, 2011			March 31, 2011
Raw materials	$	1,908,337		$	1,576,706
Finished goods	895,120			1,087,167
Total gross inventories	2,803,457			2,663,873
Less reserve for obsolescence	(115,000		)	(60,000		)
Total net inventories	$	2,688,457		$	2,603,873

Property and Equipment. Property and equipment are stated at cost, with depreciation computed over the estimated useful lives of the assets, generally three to seven years. We use the straight-line method of depreciation for property and equipment. Leasehold improvements are depreciated over the shorter of the remaining lease term or the estimated useful life of the asset. Maintenance and repairs are expensed as incurred and major additions, replacements and improvements are capitalized.

Long-Lived Assets. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. A long-lived asset is considered impaired when estimated future cash flows related to the asset, undiscounted and without interest, are insufficient to recover the carrying amount of the asset. If deemed impaired, the long-lived asset is reduced to its estimated fair value. Long-lived assets to be disposed of are reported at the lower of their carrying amount or estimated fair value less cost to sell.

Patents. The costs of applying for patents are capitalized and amortized on a straight-line basis over the lesser of the patent’s economic or legal life (20 years from the date of application in the United States). Capitalized costs are expensed if patents are not issued. We review the carrying value of our patents periodically to determine whether the patents have continuing value and such reviews could result in the conclusion that the recorded amounts have been impaired.

Income Taxes. We account for income taxes under the provisions of FASB Accounting Standards Codification (“ASC”) Topic 740, “Accounting for Income Taxes” (“ASC 740”). ASC 740 requires recognition of deferred income tax assets and liabilities for the expected future income tax consequences, based on enacted tax laws, of temporary differences between the financial reporting and tax bases of assets and liabilities. ASC 740 also requires recognition of deferred tax assets for the expected future tax effects of all deductible temporary differences, loss carryforwards and tax credit carryforwards. Deferred tax assets are then reduced, if deemed necessary, by a valuation allowance for the amount of any tax benefits which, more likely than not based on current circumstances, are not expected to be realized. As a result, no provision for income tax is reflected in the accompanying statements of operations. Should we achieve sufficient, sustained income in the future, we may conclude that some or all of the valuation allowance should be reversed. We are required to make many subjective assumptions and judgments regarding our income tax exposures. At September 30, 2011, we had no unrecognized tax benefits which would affect the effective tax rate if recognized and had no accrued interest or penalties related to uncertain tax positions.

Sales Recognition. Sales from product sales are recorded when we ship the product and title has passed to the customer, provided that we have evidence of a customer arrangement and can conclude that collection is probable. Our shipping policy is FOB Shipping Point. We recognize revenue from sales to stocking distributors when there is no right of return, other than for normal warranty claims. We have no ongoing obligations related to product sales, except for normal warranty obligations.

Research and Development Expenses. We expense research and development costs for products and processes as incurred.

Stock-Based Compensation. Stock-based compensation is presented in accordance with the guidance of ASC Topic 718, “Compensation — Stock Compensation” (“ASC 718”). Under the provisions of ASC 718, companies are required to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in our statement of operations.

Stock-based compensation expense recognized under ASC 718 for the three months ended September 30, 2011 and 2010 was $21,259 and $26,360, respectively, and $44,341 and $52,660 for the six months ended September 30, 2011 and 2010, respectively, which consisted of stock-based compensation expense related to grants of employee stock options.

Segment Reporting. We have concluded that we have one operating segment.

Recent Accounting Pronouncements. We have reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe the future adoption of any such pronouncements may be expected to cause a material impact on our financial condition or the results of our operations.

Note 3. BASIC AND DILUTED INCOME AND LOSS PER COMMON SHARE

We report both basic and diluted net income (loss) per share. Basic net income or loss per common share is computed by dividing net income or loss for the period by the weighted average number of common shares outstanding for the period. Diluted net income or loss per common share is computed by dividing the net income or loss for the period by the weighted average number of common and potential common shares outstanding during the period if the effect of the potential common shares is dilutive. The shares used in the calculation of dilutive potential common shares exclude options to purchase shares where the exercise price was greater than the average market price of common shares for the period.

Table of Contents

The following table presents the calculation of basic and diluted net loss per share:

	Three Months Ended						Six Months Ended
	September 30, 2011			September 30, 2010			September 30, 2011			September 30, 2010
Net loss	$	(469,375	)	$	(145,368	)	$	(489,751	)	$	(264,164	)
Weighted-average shares — basic	6,455,100			6,455,100			6,455,100			6,455,100
Effect of dilutive potential common shares	—			—			—			—
Weighted-average shares — diluted	6,455,100			6,455,100			6,455,100			6,455,100
Net loss per share — basic	$	(0.07	)	$	(0.02	)	$	(0.08	)	$	(0.04	)
Net loss per share — diluted	$	(0.07	)	$	(0.02	)	$	(0.08	)	$	(0.04	)
Antidilutive employee stock options	760,000			535,000			760,000			535,000

Note 4. COMMITMENTS AND CONTINGENCIES

We currently lease our facilities at 6797 Winchester Circle, Boulder, Colorado under noncancelable lease agreements through July 31, 2014. The minimum future lease payment, by fiscal year, as of September 30, 2011 is as follows:

Fiscal Year	Amount
2012 (six months remaining)	$	137,526
2013	301,469
2014	320,080
2015	108,303
Total	$	867,378

Our minimum future equipment lease payments with General Electric Capital Corporation as of September 30, 2011, by fiscal year, are as follows:

Fiscal Year	Amount
2012 (six months remaining)	$	50,937
2013	101,873
2014	8,488
Total	$	161,298

On November 11, 2011, we signed an amendment to our credit facility agreement with Silicon Valley Bank (“Silicon”), effective November 8, 2011. The terms of the credit facility include a line of credit for $2,000,000 for an interim period to December 23, 2011 at an interest rate calculated at Silicon’s prime rate, which was 4% at September 30, 2011, plus 1.25%, subject to increase upon a default. The credit facility is secured by any and all of our properties, rights and assets. Our borrowing under the credit facility is limited by our eligible receivables and inventory at the time of borrowing. The amendment has reduced our inventory borrowing base by $300,000. The credit facility requires us to meet certain financial covenants. As of September 30, 2011, we failed to meet the minimum defined quick debt ratio covenant. As a result, the lender may impose a monthly maintenance fee, requires additional financial reporting and restricts our borrowings to the beginning of each week instead of when needed. Also, as of September 30, 2011, we failed to meet our financial covenant regarding net income. Silicon may have the right to certain remedies upon our failure to meet our financial covenant, including an increase to the interest rate. We signed a forbearance agreement, including an extension to December 23, 2011, with Silicon with regard to our failure to meet our financial covenant regarding net income. At September 30, 2011, we had borrowed $691,012 from the credit facility and, under our eligible receivables and inventory limit, had an additional $782,000 available to borrow. If the amendment was in effect at September 30, 2011, under our eligible receivables and inventory limit, we would have had an additional $482,000 available to borrow. We anticipate entering into a new credit facility agreement before our current agreement expires on December 23, 2011; however, we cannot predict with certainty that this will occur.

Aside from the operating leases and credit facility commitments, we do not have any material contractual commitments requiring settlement in the future.

We are subject to regulation by the United States Food and Drug Administration (“FDA”). The FDA provides regulations governing the manufacture and sale of our products and regularly inspects us and other manufacturers to determine compliance with these regulations. We believe that we were in substantial compliance with all known regulations as of September 30, 2011. FDA inspections are conducted periodically at the discretion of the FDA. Our latest inspection by the FDA occurred in November 2009.

Note 5. SHARE-BASED COMPENSATION

The provisions of ASC 718-10-55 requires the measurement and recognition of compensation expense for all share-based payment awards made to our employees and directors, including employee stock options, based on estimated fair values. The following table summarizes stock-based compensation expense related to employee stock options and employee stock purchases for the three months ended September 30, 2011 and 2010, which was allocated as follows:

	Three Months Ended				Six Months Ended
	September 30, 2011		September 30, 2010		September 30, 2011		September 30, 2010
Cost of sales	$	658	$	823	$	1,468	$	1,646
Sales and marketing	2,253		3,268		5,024		6,536
General and administrative	15,568		18,547		32,148		37,034
Research and development	2,780		3,722		5,701		7,444
Stock-based compensation expense	$	21,259	$	26,360	$	44,341	$	52,660

Table of Contents

ITEM 2 — MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Certain statements contained in this section on Management’s Discussion and Analysis are not historical facts, including statements about our strategies and expectations with respect to new and existing products, market demand, acceptance of new and existing products, marketing efforts, technologies and opportunities, market and industry segment growth, and return on investments in products and markets. These statements are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated by the forward looking statements. All forward looking statements in this section on Management’s Discussion and Analysis are based on information available to us on the date of this document, and we assume no obligation to update such forward looking statements. Readers of this Form 10-Q are strongly encouraged to review the section entitled “Risk Factors” in our Form 10-K for the fiscal year ended March 31, 2011.

General

Encision Inc., a medical device company based in Boulder, Colorado, has developed and launched innovative technology that is emerging as a standard of care in minimally-invasive surgery. We believe that our patented AEM® (Active Electrode Monitoring) surgical instruments are changing the marketplace for electrosurgical devices and laparoscopic instruments by providing a solution to a well documented patient safety risk in laparoscopic surgery.

We were founded to address market opportunities created by the increase in minimally-invasive surgery (“MIS”) and surgeons’ preference for using electrosurgery devices in these procedures. The product opportunity was created by surgeons’ continued widespread demand for using monopolar electrosurgery instruments, which, when used in laparoscopic surgery, are susceptible to causing inadvertent collateral tissue damage outside the surgeon’s field of view. The risk of unintended electrosurgical burn injury to the patient in laparoscopic surgery has been well documented. This risk poses a threat to patient safety and creates liability exposure for surgeons and hospitals that do not adequately address the issue.

Our patented AEM technology provides surgeons with the desired tissue effects, while preventing stray electrosurgical energy that can cause unintended and unseen tissue injury. AEM laparoscopic instruments are equivalent to conventional instruments in functionality, but they incorporate “active electrode monitoring” technology to dynamically and continuously monitor the flow of electrosurgical current, thereby helping to prevent patient injury. With our “shielded and monitored” instruments, surgeons are able to perform electrosurgical procedures more safely and effectively than when using conventional instruments. In addition, our AEM instruments are cost competitive with conventional “non-shielded, non-monitored” instruments. The result is advanced patient safety at comparable cost and with no change in surgeon technique.

AEM technology has been recommended and endorsed by sources from various groups involved in MIS. Surgeons, nurses, biomedical engineers, the medicolegal community, malpractice insurance carriers and electrosurgical device manufacturers advocate the use of AEM technology. Recommendations from the malpractice insurance and medicolegal communities complement the broad clinical endorsements AEM technology has garnered over the past few years.

We have focused our marketing strategies to date on expanding the market awareness of the AEM technology and our broad independent endorsements and have continued efforts to improve and expand the AEM product line. Accordingly, we are currently focusing on updating our accepted AEM instruments to include ergonomics and user functionalities for which surgeons have been expressing a preference. When a hospital or surgery center changes to AEM technology, we receive recurring sales from sales of replacement instruments. We believe that there is no directly competing technology to supplant AEM products. The replacement market of reusable and disposable AEM products in hospitals and surgery centers that use our AEM technology represented over 90% of our sales during the six months ended September 30, 2011. This sales stream is expected to grow as the base of accounts that switch to AEM technology continues to grow. In addition, we intend to develop disposable versions of more of our AEM products in order to meet market demands and expand our sales opportunities.

During the six months ended September 30, 2011, we used $11,021 of cash for our operations and used $335,117 for investments in property and equipment. As of September 30, 2011, we had $15,126 in cash and cash equivalents available to fund future operations, a decrease of $104,882 from March 31, 2011. As of September 30, 2011, we borrowed $691,012 from our $2,000,000 amended credit facility, an increase of $256,012 from March 31, 2011. Our working capital was $1,657,935 at September 30, 2011 compared to $2,301,650 at March 31, 2011.

During the quarter ended September 30, 2011, we initiated a voluntary recall of electrode tips used in our AEM surgical systems after determining that certain tips could become susceptible to breaking off as a consequence of aggressive cleaning of the tip. The tips covered by the voluntary recall are our ES388X Series Reusable Suction-Irrigation Electrodes. All of the affected instruments will be replaced at no charge to the customer. We have developed a replacement instrument and are currently working with the FDA to obtain approval of the replacement. Until the FDA provides its approval, we will not be able to provide replacement products to customers. In the interim, we have provided customers with the prior version of the product, which is not susceptible to the same issues as the recalled product. In connection with the voluntary recall, we recorded a one-time charge of $430,000 for the quarter ended September 30, 2011, which included non-cash charges of $105,000, for removal of the instruments that are currently carried in inventory and for an increase to warranty accrual.

Historical Perspective

We were organized in 1991 and spent several years developing the AEM monitoring system and protective sheaths to adapt to conventional electrosurgical instruments. During this period, we conducted product trials and applied for patents with the United States Patent Office and international patent agencies. Patents were issued to us in 1994, 1996, 1997, 1998, 2002 and 2009.

As we evolved, it became clear to us that our AEM technology needed to be integrated into the standard laparoscopic instrument design. As the development program proceeded, it also became apparent that the merging of electrical and mechanical engineering skills in the instrument

Table of Contents

development process for our patented, integrated electrosurgical instruments was a complex and difficult task. As a result, instruments with integrated AEM technology were not completed for several years. Prior to offering a full range of laparoscopic electrosurgical instrumentation, it was difficult for hospitals to commit to the AEM solution, as we did not have adequate comparable surgical instrument options to meet surgeons’ demands. As of fiscal year 2005, a sufficiently broad product line was available to provide surgical suites with AEM instruments in most of the designs common for laparoscopic surgery.

After the launch of this line of AEM instruments over the past six years, we continue our focus on developing next generation versions of our AEM instruments to better meet market demands, particularly the demand for improved ergonomics and simplified user functionalities. This strategy coincides with the independent endorsements of our AEM technology and the recommendations from the malpractice insurance and medicolegal communities.

Outlook

Installed Base of AEM Monitoring Equipment: We believe that sales of our installed base of AEM products will increase sales as the inherent risks associated with monopolar laparoscopic electrosurgery become more widely acknowledged and as we focus on increasing our sales efficiency. We expect that the replacement sales of electrosurgical instruments and accessories will also increase as additional facilities adopt AEM technology. We anticipate that the efforts to improve the productivity of sales representatives carrying the AEM product line, along with the introduction of next generation products, may provide the basis for increased sales and profitable operations. However, these measures, or any others that we may adopt, may not result in either increased sales or profitable operations.

We believe that the unique performance of the AEM technology and our breadth of independent endorsements provide an opportunity for continued market share growth. In our view, market awareness and awareness of the clinical credibility of the AEM technology, as well as awareness of our endorsements, are continually improving, and we expect this awareness to benefit our sales efforts for the remainder of fiscal year 2012. Our objectives in the remainder of fiscal year 2012 are to maintain expense controls while optimizing sales execution, to expand market awareness of the AEM technology and to maximize the number of additional hospital and surgery center accounts switching to AEM instruments while retaining existing customers. In addition, acceptance of AEM products depends on surgeons’ preference for our instruments, which depends on factors such as ergonomics and ease of use in addition to the technological and safety advantages of AEM products. If surgeons prefer other instruments to our instruments, our business results will suffer.

Possibility of Operating Losses: We have an accumulated deficit of $16,519,118 at September 30, 2011. Operating funds have been provided primarily by issuances of our common stock, the exercise of stock options to purchase our common stock and, in recent years, by operating profits. Should our liquidity be diminished in the future because of operating losses, we may be required to seek additional capital. We have made strides toward improving our operating results but due to the ongoing need to develop, optimize and train our direct sales managers and the independent sales representative network, the need to support the development of refinements to our product line, and the need to increase sustained sales to a level adequate to cover fixed and variable operating costs, we may operate at a net loss. Sustained losses, or our inability to generate sufficient cash flow from operations to fund our obligations, may result in a need to raise additional capital.

Revenue Growth: Our product revenue growth has decreased from weakness in the medical device industry as a result of a decrease in the number of laparoscopic procedures. We expect to generate increased product revenue in the U.S. from sales to new customers and from expanded sales to existing customers as the medical device industry stabilizes and our network of direct and independent sales representatives becomes more efficient. We believe that the visibility and credibility of the independent clinical endorsements for AEM technology will contribute to new accounts and increased product revenue in fiscal year 2012. We also expect to increase market share through promotional programs of placing our AEM monitors at no charge into hospitals that commit to standardize AEM instruments. However, all of these efforts to increase market share and grow product revenue will depend in part on our ability to expand the efficiency and effective coverage range of our direct and independent sales representatives. Increased service revenue represents design and development service revenue from our agreements with Intuitive Surgical, Inc. and Boston Scientific Corporation due to our efforts to obtain increased revenue by working with strategic partners. We expect that this level of service revenue will approximately continue throughout the remainder of fiscal year 2012.

We also have longer term initiatives in place to improve our prospects. We expect that development of next generation versions of our AEM products will better position our products in the marketplace and improve our retention rate at hospitals and surgery centers that have changed to AEM technology, enabling us to grow our sales. We are exploring overseas markets to assess opportunities for sales growth internationally. Finally, we intend to explore opportunities to capitalize on our proven AEM technology via licensing arrangements and strategic alliances. These efforts to generate additional sales and further the market penetration of our products are longer term in nature and may not materialize. Even if we are able to successfully develop next generation products or identify potential international markets or strategic partners, we may not be able to capitalize on these opportunities.

Gross Profit and Gross Margins: Gross profit and gross margins can be expected to fluctuate from quarter to quarter as a result of product sales mix, sales volume and development revenue. Gross margins on products manufactured or assembled by us are expected to improve at higher levels of production and sales.

Manufacturing: As sales increase, we expect to increase gross profit and gross margins by manufacturing our scissor inserts internally.

Sales and Marketing Expenses: We continue our efforts to expand domestic and international distribution capability, and we believe that sales and marketing expenses will decrease as a percentage of net sales with increasing sales volume.

Research and Development Expenses: Research and development expenses are expected to increase to support development of refinements to our AEM product line, which will further expand the instrument options for surgeons.

Table of Contents

Results of Operations

For the three months ended September 30, 2011 compared to the three months ended September 30, 2010.

Product Revenue. Product revenue for the quarter ended September 30, 2011 was $2,830,369 compared to $2,865,799 for the quarter ended September 30, 2010, a decrease of 1%. The decrease is attributable to weakness in the medical device industry and to business lost from accounts that stopped using AEM technology and to outside reprocessors who reprocess our product for resale. This was partially offset by addition of new accounts. We opened eight new accounts for AEM technology in the three months ended September 30, 2011 versus four new accounts for AEM technology in the three months ended September 30, 2010.

Service Revenue. Service revenue for the quarter ended September 30, 2011 was $436,789 compared to none for the quarter ended September 30, 2010. Service revenue represents design and development service revenue from our agreements with Intuitive Surgical, Inc. and Boston Scientific Corporation due to our efforts to obtain increased revenue by working with strategic partners.

Gross profit. Product gross profit for the quarter ended September 30, 2011 of $1,305,125 represented a decrease of 29% from gross profit of $1,834,223 for the quarter ended September 30, 2010. Gross profit as a percentage of sales (gross margins) decreased from 64% for the quarter ended September 30, 2010 to 46% for the quarter ended September 30, 2011. During the quarter ended September 30, 2011, we initiated a voluntary recall of electrode tips used in our AEM surgical systems after determining that certain tips could become susceptible to breaking off as a consequence of aggressive cleaning of the tip. The tips covered by the voluntary recall are our ES388X Series Reusable Suction-Irrigation Electrodes. All of the affected instruments will be replaced at no charge to the customer. We have developed a replacement instrument and are currently working with the FDA to obtain approval of the replacement. Until the FDA provides its approval, we will not be able to provide replacement products to customers. In the interim, we have provided customers with the prior version of the product, which is not susceptible to the same issues as the recalled product. In connection with the voluntary recall, we recorded a one-time charge of $430,000 for the quarter ended September 30, 2011, which included non-cash charges of $105,000, for removal of the instruments that are currently carried in inventory and for an increase to warranty accrual. For the six months ended September 30, 2011, revenue from this product represented less than 5% of our total net revenue. The gross profit margin decrease from the second quarter of fiscal year 2011 was due to the charge for a voluntary recall, and an increase, as a percentage of revenue, of lower gross margin revenue. Excluding the voluntary recall cost, gross profit margin for the second quarter of fiscal year 2012 was 61%.

Service gross profit for the quarter ended September 30, 2011 of $261,072 represented an increase of $261,072 from no gross profit for the quarter ended September 30, 2010.

Sales and marketing expenses. Sales and marketing expenses of $1,212,878 for the quarter ended September 30, 2011 represented an increase of 13% from sales and marketing expenses of $1,075,664 for the quarter ended September 30, 2010. The increase was the result of increased compensation of our direct sales representatives, as a result of an increase in direct sales representatives, increased cost and travel for meetings of our sales representatives, which last year occurred in our first quarter that ended June 30, 2010, and recruiting fees and sales samples costs for the increased direct sales representatives. The increase in such costs was partially offset by a reclassification of one person from our sales classification into our general and administrative classification.

General and administrative expenses. General and administrative expenses of $462,907 for the quarter ended September 30, 2011 represented an increase of 17% from general and administrative expenses of $396,968 for the quarter ended September 30, 2010. The increase was the result of an increase in severance cost and a reclassification of one person from our sales classification into our general and administrative classification. The increase in such costs was partially offset by a decrease in outside services and compensation.

Research and development expenses. Research and development expenses of $342,173 for the quarter ended September 30, 2011 represented a decrease of 31% compared to $494,578 for the quarter ended September 30, 2010. The decrease was the result of a decrease in outside services and inventory usage and test materials. The decrease in such costs was partially offset by increased compensation and increased small tools and test materials costs.

Net loss. Net loss was $469,375 for the quarter ended September 30, 2011 compared to a net loss of $145,368 for the quarter ended September 30, 2010. The net loss increase was a result, primarily, of the cost of the product recall and a slight increase in operating expenses. The net loss increase was partially offset by the contribution of service revenue, as discussed above.

For the six months ended September 30, 2011 compared to the six months ended September 30, 2010.

Product Revenue. Product revenue for the six months ended September 30, 2011 was $5,663,574 compared to $5,729,732 for the six months ended September 30, 2010, a decrease of 1%. The decrease is attributable to weakness in the medical device industry and to business lost from accounts that stopped using AEM technology and to outside reprocessors who reprocess our product for resale. This was partially offset by addition of new accounts. We opened fourteen new accounts for AEM technology in the three months ended September 30, 2011 versus six new accounts for AEM technology in the six months ended September 30, 2010.

Service Revenue. Service revenue for the six months ended September 30, 2011 was $787,578 compared to $48,688 for the six months ended September 30, 2010, an increase of $738,890. Service revenue represents design and development service revenue from our agreements with Intuitive Surgical, Inc. and Boston Scientific Corporation due to our efforts to obtain increased revenue by working with strategic partners.

Gross profit. Product gross profit for the six months ended September 30, 2011 of $2,877,654 represented a decrease of 22% from gross profit of $3,674,665 for the six months ended September 30, 2010. Gross profit as a percentage of sales (gross margins) decreased from 64% for the six months ended September 30, 2010 to 51% for the six months ended September 30, 2011. The gross profit margin decrease from the first six months of fiscal year 2011 was due to the items that were explained above. Excluding the voluntary recall cost, gross profit margin for the second quarter of fiscal year 2012 was 58%. Service gross profit for the six months ended September 30, 2011 of $467,669 represented an increase of $463,783 from gross profit of $3,886 for the six months ended September 30, 2010.

Sales and marketing expenses. Sales and marketing expenses of $2,250,318 for the six months ended September 30, 2011 represented a decrease of 0.5% from sales and marketing expenses of $2,261,471 for the six months ended September 30, 2010. The slight decrease was the result of decreased compensation of our direct sales representatives, a reclassification of one person from our sales classification into our general and administrative

Table of Contents

classification, decreased commissions for independent sales representatives and decreased outside services for marketing. The decrease in such costs was partially offset by an increase in public relations costs, recruiting fees, sales samples and travel and meals.

General and administrative expenses. General and administrative expenses of $881,696 for the six months ended September 30, 2011 represented an increase of 11% from general and administrative expenses of $792,876 for the six months ended September 30, 2010. The increase was the result of an increase in severance cost, a reclassification of one person from our sales classification into our general and administrative classification and legal fees. The increase in such costs was partially offset by a decrease in compensation and outside services.

Research and development expenses. Research and development expenses of $672,765 for the six months ended September 30, 2011 represented a decrease of 22% compared to $866,549 for the six months ended September 30, 2010. The decrease was the result of a decrease in outside services and inventory and test materials usage. The decrease in such costs was partially offset by increased small tools costs.

Net loss. Net loss was $489,751 for the six months ended September 30, 2011 compared to a net loss of $264,164 for the six months ended September 30, 2010. The net loss increase was a result of a significant decrease in operating expenses and the contribution of service revenue. The net loss decrease was partially offset by a decrease in sales and by a significant decrease in gross profit, as a percentage of sales, as discussed above.

The results of operations for the three months ended September 30, 2011 should not be taken as an indication of the results of operations for all or any part of the balance of the fiscal year.

Liquidity and Capital Resources

At September 30, 2011, operating funds have been provided primarily by issuances of our common stock, the exercise of stock options to purchase our common stock and, in recent years, by operating profits. Operating funds totaled $19,827,702 from our inception through September 30, 2011.

On November 10, 2011, we signed a third amendment to our credit facility agreement with Silicon, effective November 8, 2011. The terms of the credit facility include a line of credit for $2,000,000 for an interim period to December 23, 2011 at an interest rate calculated at Silicon’s prime rate, which was 4% at September 30, 2011, plus 1.25%, subject to increase upon a default. The credit facility is secured by any and all of our properties, rights and assets. Our borrowing under the credit facility is limited by our eligible receivables and inventory at the time of borrowing. The credit facility requires us to meet certain financial covenants. As of September 30, 2011, we failed to meet the minimum defined quick debt ratio covenant. As a result, the lender may impose a monthly maintenance fee, requires additional financial reporting and restricts our borrowings to the beginning of each week instead of when needed. Also, as of September 30, 2011, we failed to meet our financial covenant regarding net income. Silicon may have the right to certain remedies upon our failure to meet our financial covenant, including an increase to the interest rate. We signed a forbearance agreement, including an extension to December 23, 2011, with Silicon with regard to our failure to meet our financial covenant regarding net income. At September 30, 2011, we had borrowed $691,012 from the credit facility and, under our eligible receivables and inventory limit, had an additional $782,000 available to borrow.

Our operations used $11,021 of cash during the six months ended September 30, 2011 on net revenue of $6,451,152. Cash was used by an increased loss and an increase to inventories. Cash used was partially offset by an increase to accrued compensation and other accrued liabilities. The amounts of cash used by operations for the three months ended September 30, 2011 are not indicative of the expected amounts of cash to be generated from or used in operations in fiscal year 2012. During the three months ended September 30, 2011, we invested $335,117 in the acquisition of property and equipment. As of September 30, 2011, we had $15,126 in cash and cash equivalents available to fund future operations and had borrowed $691,012 from our credit facility. Working capital was $1,657,935 at September 30, 2011 compared to $2,301,650 at March 31, 2011. Current liabilities were $2,269,335 at September 30, 2011, compared to $1,656,874 at March 31, 2011. The increase in current liabilities at September 30, 2011 was caused, principally, by increasing borrowings from our line of credit and an increase to other accrued liabilities.

If we are not successful in maintaining profitability and positive cash flow, additional capital may be required to maintain ongoing operations. We have explored and are continuing to explore options to provide additional financing to fund future operations as well as other possible courses of action. Such actions include, but are not limited to, securing additional lines of credit, sales of debt or equity securities (which may result in dilution to existing shareholders), licensing of technology, strategic alliances and other similar actions. There can be no assurance that we will be able to obtain additional funding (if needed), on acceptable terms or at all, through a sale of our common stock, loans from financial institutions or other third parties, or any of the actions discussed above. If we cannot sustain profitable operations, and additional capital is unavailable, lack of liquidity could have a material adverse effect on our business viability, financial position, results of operations and cash flows.

We currently lease our facilities at 6797 Winchester Circle, Boulder, Colorado under noncancelable lease agreements through July 31, 2014. The minimum future lease payment by fiscal year as of September 30, 2011 is as follows:

Fiscal Year	Amount
2012 (six months remaining)	$	137,526
2013	301,469
2014	320,080
2015	108,303
Total	$	867,378

Our minimum future equipment lease payments with General Electric Capital Corporation as of September 30, 2011, by fiscal year, are as follows:

Fiscal Year	Amount
2012 (six months remaining)	$	50,937
2013	101,873
2014	8,488
Total	$	161,298

Table of Contents

As of September 30, 2011, the following table shows our contractual obligations for the periods presented:

	Payment due by period
Contractual obligations	Totals		Less than 1 year		1-3 years		3-5 years		More than 5 years
Line of credit obligations	$	691,012	$	691,012	$	—	$	—	$	—
Operating lease obligations	1,028,676		390,135		638,541		—		—
Total	$	1,719,688	$	1,081,147	$	638,541	$	—	$	—

Aside from the operating leases and credit facility commitments, we do not have any material contractual commitments requiring settlement in the future.

Our fiscal year 2012 operating plan is focused on increasing new accounts, retaining existing customers, growing sales, increasing gross profits and conserving cash. We are investing in research and development efforts to develop next generation versions of the AEM product line. We have invested in manufacturing property and equipment to manufacture disposable scissors inserts internally and reduce our cost of sales. We cannot predict with certainty the expected sales, gross profit, net income or loss and usage of cash and cash equivalents for fiscal year 2012. On November 10, 2011, we signed a third amendment to our credit facility agreement with Silicon, effective November 8, 2011. We intend to enter into a new credit facility agreement prior to the expiration of the current credit facility. Unless our line of credit is not renewed on December 23, 2011, we believe that our cash resources and credit facility will be sufficient to fund our operations for at least the next twelve months. If we are unable to manage our business operations in line with budget expectations, it could have a material adverse effect on our business viability, financial position, results of operations and cash flows. If we are not successful in continuing profitability and positive cash flow, and renewing our line of credit, additional capital may be required to maintain ongoing operations.

Income Taxes

As of March 31, 2011, net operating loss carryforwards totaling approximately $13.3 million are available to reduce taxable income in the future. The net operating loss carryforwards expire, if not previously utilized, at various dates beginning in the fiscal year ending March 31, 2012. We have not paid income taxes since our inception. The Tax Reform Act of 1986 and other income tax regulations contain provisions which may limit the net operating loss carryforwards available to be used in any given year if certain events occur, including changes in ownership interests. We have established a valuation allowance for the entire amount of our deferred tax asset since inception due to our history of losses. Should we achieve sufficient, sustained income in the future, we may conclude that some or all of the valuation allowance should be reversed. If some or all of the valuation allowance were reversed, then, to the extent of the reversal, a tax benefit would be recognized which would result in an increase to net income.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, sales and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to bad debts, inventories, sales returns, warranty, contingencies and litigation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe the following critical accounting policies affect the more significant judgments and estimates used in the preparation of our financial statements.

We maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. If the financial condition of our customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances would be required, which would increase our expenses during the periods in which any such allowances were made. The amount recorded as a provision for bad debts in each period is based upon our assessment of the likelihood that we will be paid on our outstanding receivables, based on customer-specific as well as general considerations. To the extent that our estimates prove to be too high, and we ultimately collect a receivable previously determined to be impaired, we may record a reversal of the provision in the period of such determination.

We provide for the estimated cost of product warranties at the time sales are recognized. While we engage in extensive product quality programs and processes, including actively monitoring and evaluating the quality of our component suppliers, we have experienced some costs related to warranties. The warranty accrual is based on historical experience and is adjusted based on current experience. Should actual warranty experience differ from our estimates, revisions to the estimated warranty liability would be required.

We reduce inventory for estimated obsolete or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based on assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. Any write-downs of inventory would reduce our reported net income during the period in which such write-downs were applied. To the extent that our estimates prove to be too high, and we ultimately utilize or sell inventory previously determined to be impaired, we may record a reversal of the provision in the period of such determination.

We recognize deferred income tax assets and liabilities for the expected future income tax consequences, based on enacted tax laws, of temporary differences between the financial reporting and tax bases of assets and liabilities. Deferred tax assets are then reduced, if deemed necessary, by a

Table of Contents

PART II.	OTHER INFORMATION

ITEM 6	EXHIBITS

	The following exhibits are filed with this report on Form 10-Q or are incorporated by reference:

		31.1	Certification of Chief Executive Officer under Rule 13a-14(a) of the Exchange Act (filed herewith).

		31.2	Certification of Principal Financial and Accounting Officer under Rule 13a-14(a) of the Exchange Act (filed herewith).

		32.1	Certifications of Chief Executive Officer and Principal Financial and Accounting Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith).

		101	The following materials from Encision Inc.’s Quarterly Report on Form 1-Q for the quarter ended September 30, 2011, formatted in XBRL (Extensible Business Reporting Language): (i) the unaudited Condensed Balance Sheets, (ii) the unaudited Condensed Statements of Income, (iii) the unaudited Condensed Statements of Cash Flows, and (iv) Notes to Condensed Financial Statements, tagged at Level I.

Users of the XBRL data are advised pursuant to Rule 406T of Regulation S-T that this interactive data file is deemed not filed or part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.

			Page
			Number

PART I.	FINANCIAL INFORMATION

ITEM 1	-	Condensed Interim Financial Statements:

	-	Condensed Balance Sheets as of September 30, 2011 and March 31, 2011	3

	-	Condensed Statements of Operations for the Three Months Ended September 30, 2011 and 2010	4

	-	Condensed Statements of Operations for the Six Months Ended September 30, 2011 and 2010	5

	-	Condensed Statements of Cash Flows for the Six Months Ended September 30, 2011 and 2010	6

	-	Notes to Condensed Interim Financial Statements	7

ITEM 2	-	Management’s Discussion and Analysis of Financial Condition and Results of Operations	11

ITEM 4	-	Controls and Procedures	17

PART II.	OTHER INFORMATION

ITEM 6	-	Exhibits	18

SIGNATURE			19

November 14, 2011		/s/ Marcia McHaffie
Date		Marcia McHaffie
		Controller
		Principal Accounting Officer & Principal Financial Officer